Table 3. Patient disease molecular characteristics.
| Cancer type | Duration of treatment (cycles) | Best tesponse | Reason for tiscontinuation | Mutation of interest | RAS pathway mutation | Other mutated genes |
|---|---|---|---|---|---|---|
| Non-small cell lung cancer (NOS) | 2 | PD | Disease progression | NF1 p. E8* | N/A | BRCA1, CDH1 |
| Adenocarcinoma of the gallbladder | 2 | PD | Disease progression | STK11 p.E199* | N/A | ATM, ERCC2, GNAS, MAP3XK1, UGT1A7 |
| Adenocarcinoma of the lung | 2 | PD | Pericardial effusion (unrelated to treatment) | NF1 R1038T | HRAS E91Q¥ | NFE2L2, TP53, CDH1, RIT1, EGFR G719A (¥) |
| Adenocarcinoma of the lung | 1 | CR | Pericardial effusion (related to treatment) | STK11 c.375-2del and c.375-G>C | N/A | SMAD4, BRCA2 |
| Adenocarcinoma of the pancreas | 1 | PD | Disease progression | NF1 c.7190C>T and c.7253C>T | KRAS G12D | CDKN2A, TP53, SMAD4, CSF1R |
| Adenocarcinoma of the lung | 6 | SD | Disease progression | NF1 p.Y489C | N/A | MAP2K2, TP53 |
| Adenocarcinoma of the lung | 2 | PD | Disease progression | STK11 Exon 1 E33X | KRAS G12C | TP53 |
| Adenocarcinoma of the endocervix | 2 | PD | Disease progression | STK11 L282fs*5 | KRAS G12C | CDKN2A |
¥, identified through plasma genotyping (circulating tumor DNA). NOS, not otherwise specified; SD, stable disease; CR, complete response; PD, progression of disease; N/A, not applicable.